+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Small Nucleic Acid Therapies Market - Global Forecast 2026-2032- Product Image
Small Nucleic Acid Therapies Market - Global Forecast 2026-2032- Product Image
Sale

Small Nucleic Acid Therapies Market - Global Forecast 2026-2032

  • Report

  • 183 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6085487
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Small Nucleic Acid Therapies Market is projected to reach USD 7.33 Billion in 2026. It is expected to continue growing at a CAGR of 26.34%, reaching USD 29.85 Billion by 2032.

Small Nucleic Acid Therapies: Executive Overview

Small nucleic acid therapies use short RNA or DNA sequences to modulate disease biology through mechanisms such as gene silencing, transcript correction, or targeted immune activation. The field includes antisense oligonucleotides, small interfering RNA, microRNA-based approaches, aptamers, and related constructs. Clinical progress has been supported by advances in sequence design, chemical modification, delivery systems, biomarker development, and regulatory experience. Key strategic considerations include tissue targeting, durability of response, immunogenicity, manufacturing consistency, and the ability to demonstrate meaningful clinical benefit in genetically or molecularly defined populations.

From Molecular Proof to Delivery and Lifecycle Execution

The landscape is shifting from demonstrating that nucleic acids can alter a target toward solving delivery, repeat dosing, and treatment durability across organs. Liver-directed approaches benefit from established conjugation and nanoparticle strategies, while delivery to the central nervous system, muscle, tumors, and other tissues remains more technically demanding. Developers are also placing greater emphasis on clinically relevant endpoints, patient selection, companion diagnostics, scalable manufacturing, and post-approval evidence. These shifts favor integrated development programs that connect molecular design with formulation, clinical operations, and long-term safety monitoring.

Artificial Intelligence Accelerates Design, Selection, and Development Workflows

Artificial intelligence can contribute across the therapy lifecycle by analyzing sequence-activity relationships, predicting off-target interactions, prioritizing chemical modifications, and identifying delivery formulations for experimental testing. In clinical development, machine learning may support biomarker discovery, patient stratification, trial-site planning, and interpretation of high-dimensional genomic or transcriptomic data. Its value depends on high-quality, well-annotated datasets and rigorous experimental validation. Governance is essential because model bias, data leakage, reproducibility limitations, and uncertain biological causality can undermine decisions if computational outputs are treated as clinical evidence without confirmation.

Regional Dynamics Span Mature Regulation and Expanding Biologic Innovation

North America combines advanced translational research, specialized clinical infrastructure, and regulatory experience in oligonucleotide development. Europe benefits from strong academic networks, coordinated scientific standards, and active work on rare diseases and advanced therapies. Asia-Pacific is supported by substantial biomedical research capacity, growing manufacturing expertise, and increasing clinical-trial activity, particularly in China, Japan, South Korea, and Australia. Latin America is relevant for patient recruitment, specialist-care development, and access planning, although regulatory and infrastructure variation can complicate execution. The Middle East is building research and healthcare capabilities in selected hubs, while Africa presents important unmet-need opportunities alongside constraints in specialized diagnostics, trial infrastructure, and supply continuity.

Economic and Security Groups Shape Access, Standards, and Collaboration

ASEAN offers a diverse set of healthcare systems and an expanding base for regional clinical development, with differences in regulation, reimbursement, and specialized-care capacity requiring country-specific planning. BRICS members contribute substantial scientific, manufacturing, and patient-access capabilities, but their policy environments and healthcare resources vary considerably. The European Union benefits from shared regulatory structures while retaining national differences in pricing and reimbursement. G7 countries provide deep research, capital, and clinical expertise. GCC states are strengthening precision-medicine infrastructure and international partnerships, whereas NATO members collectively represent broad biomedical capacity but operate under varied national health policies and procurement systems.

Country Priorities Reflect Distinct Science, Regulation, and Healthcare Capacity

The United States and Canada combine strong research ecosystems with experienced clinical-trial networks and established pathways for advanced therapeutics. The United Kingdom, France, Germany, Italy, and Spain offer substantial academic and healthcare capabilities, with access decisions shaped by national and European processes. China is expanding translational research, domestic manufacturing, and clinical-development capacity; Japan emphasizes rigorous regulatory and clinical pathways for innovative medicines; and South Korea is developing biotechnology infrastructure and manufacturing expertise. Australia supports early-phase research and international trials. India is strengthening biotechnology and pharmaceutical capabilities, while Brazil and Mexico provide important regional research and patient-access platforms. Russia retains scientific and clinical assets but faces collaboration, supply-chain, and policy constraints that can affect international development programs.

Prioritize Delivery, Evidence Quality, and Access-Ready Development

Industry leaders should align target selection with a credible delivery strategy before committing to large clinical programs, using tissue biology and pharmacodynamic evidence to guide construct and formulation choices. Programs should incorporate early assessment of immunogenicity, off-target effects, repeat-dose tolerability, manufacturing comparability, and long-term follow-up requirements. Biomarker-driven enrollment can improve biological signal detection, while adaptive operational planning can address rare-disease recruitment challenges. Regional execution should be tailored to regulatory expectations, diagnostic availability, specialist capacity, and reimbursement structures. Finally, organizations should establish transparent artificial-intelligence governance, protect patient and genomic data, and maintain a portfolio balance across delivery technologies, indications, and development stages.

Methodology Combines Scientific, Clinical, Regulatory, and Geographic Evidence

This executive summary uses a structured qualitative synthesis of the small nucleic acid therapy field. The assessment considers therapeutic modalities, biological mechanisms, delivery technologies, clinical-development practices, regulatory considerations, manufacturing requirements, artificial-intelligence applications, and healthcare-system conditions. Regional, group, and country perspectives are integrated by examining research capacity, clinical-trial infrastructure, policy environments, specialist-care access, diagnostics, manufacturing, and cross-border collaboration. Claims are limited to established industry characteristics and observable strategic themes; no market estimates, market shares, forecasts, or company-specific claims are included.

Execution Discipline Will Determine the Next Phase of Small Nucleic Acid Therapies

Small nucleic acid therapies have moved beyond proof of concept in selected settings, but broader impact depends on solving delivery, durability, safety, manufacturing, and access challenges together. Regional diversity creates opportunities for research and clinical development while requiring careful localization of regulatory and healthcare strategies. Artificial intelligence can improve prioritization and efficiency, but only when paired with validated data, laboratory confirmation, and responsible oversight. Leaders that connect molecular innovation with robust evidence generation, scalable production, and patient-centered access planning will be best positioned to translate the platform’s potential into durable clinical value.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Small Nucleic Acid Therapies Market, by Therapy Type
7.1. Introduction
7.2. Antisense Oligonucleotides
7.2.1. RNase H-dependent Oligonucleotides
7.2.1.1. Fomivirsen
7.2.1.2. Inotersen
7.2.1.3. Mipomersen
7.2.2. Steric-Blocker Oligonucleotides
7.2.2.1. Eteplirsen
7.2.2.2. Golodirsen
7.2.2.3. Nusinersen
7.3. Aptamers
7.3.1. DNA Aptamers
7.3.2. RNA Aptamers
7.4. miRNA Therapeutics
7.5. mRNA Therapeutics
7.6. piRNA Therapeutics
7.7. siRNA Therapeutics
7.7.1. Givosiran
7.7.2. Patisiran
8. Small Nucleic Acid Therapies Market, by Route of Administration
8.1. Introduction
8.2. Oral Route
8.3. Parenteral Route
8.3.1. Intramuscular
8.3.2. Intravenous
8.3.3. Subcutaneous
9. Small Nucleic Acid Therapies Market, by Delivery Mechanism
9.1. Introduction
9.2. GalNAc Conjugation
9.3. Lipid Nanoparticles (LNPs)
9.4. Polymer-Based Carriers
9.5. Viral Vectors
10. Small Nucleic Acid Therapies Market, by Therapeutic Application
10.1. Introduction
10.2. Cardiovascular Diseases
10.3. Genetic Disorders
10.3.1. Duchenne Muscular Dystrophy (DMD)
10.3.2. Spinal Muscular Atrophy (SMA)
10.4. Infectious Diseases
10.4.1. Bacterial Infections
10.4.2. Viral Infections
10.5. Inflammatory & Autoimmune Diseases
10.5.1. Psoriasis
10.5.2. Rheumatoid arthritis
10.6. Neurological Disorders
10.6.1. Alzheimer Disease
10.6.2. Parkinson Disease
10.7. Oncology
10.7.1. Glioblastoma
10.7.2. Hepatocellular Carcinoma
10.8. Ophthalmic Diseases
11. Small Nucleic Acid Therapies Market, by End User
11.1. Introduction
11.2. Academic & Research Institutes
11.3. Contract Research Organizations
11.4. Hospitals
11.5. Pharmaceutical & Biotechnology Companies
11.6. Specialty Clinics
12. Small Nucleic Acid Therapies Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Small Nucleic Acid Therapies Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Small Nucleic Acid Therapies Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. ADARx Pharmaceuticals, Inc.
16.2. Alnylam Pharmaceuticals, Inc.
16.3. AstraZeneca PLC
16.4. Avidity Biosciences
16.5. BioNTech SE
16.6. bluebird bio, Inc.
16.7. Comanche Biopharma Corp.
16.8. Creyon Bio, Inc.
16.9. Eleven Therapeutics
16.10. Ferring B.V.
16.11. GenScript Biotech Corporation
16.12. Ionis Pharmaceuticals, Inc.
16.13. Moderna, Inc.
16.14. Nogra Pharma Limited
16.15. Novartis AG
16.16. Novo Nordisk A/S
16.17. OliX Pharmaceuticals, Inc.
16.18. Pfizer Inc.
16.19. Ractigen Therapeutics
16.20. Regulus Therapeutics Inc.
16.21. SANOFI WINTHROP INDUSTRIE
16.22. Sarepta Therapeutics, Inc.
16.23. Silence Therapeutics
16.24. Sirnaomics Ltd.
16.25. Stoke Therapeutics, Inc.
16.26. Switch Therapeutics
16.27. Tevard Biosciences
16.28. Wave Life Sciences Ltd.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Small Nucleic Acid Therapies Market, Years Considered for the Study
FIGURE 2. Global Small Nucleic Acid Therapies Market, Research Design
FIGURE 3. Global Small Nucleic Acid Therapies Market, Research Framework
FIGURE 4. Global Small Nucleic Acid Therapies Market, Data Triangulation
FIGURE 5. Global Small Nucleic Acid Therapies Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Small Nucleic Acid Therapies Market Size, by Therapy Type, 2025 vs 2032 (%)
FIGURE 7. Global Small Nucleic Acid Therapies Market Size, by Therapy Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Small Nucleic Acid Therapies Market Size, by Route of Administration, 2025 vs 2032 (%)
FIGURE 9. Global Small Nucleic Acid Therapies Market Size, by Route of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Small Nucleic Acid Therapies Market Size, by Delivery Mechanism, 2025 vs 2032 (%)
FIGURE 11. Global Small Nucleic Acid Therapies Market Size, by Delivery Mechanism, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Small Nucleic Acid Therapies Market Size, by Therapeutic Application, 2025 vs 2032 (%)
FIGURE 13. Global Small Nucleic Acid Therapies Market Size, by Therapeutic Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Small Nucleic Acid Therapies Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Small Nucleic Acid Therapies Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Small Nucleic Acid Therapies Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Small Nucleic Acid Therapies Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Small Nucleic Acid Therapies Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Small Nucleic Acid Therapies Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Small Nucleic Acid Therapies Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Small Nucleic Acid Therapies Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Small Nucleic Acid Therapies Market Segmentation & Coverage
TABLE 2. Global Small Nucleic Acid Therapies Market Size, 2017-2032 (USD Million)
TABLE 3. Global Small Nucleic Acid Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 4. Global Antisense Oligonucleotides Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Antisense Oligonucleotides Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Antisense Oligonucleotides Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global RNase H-dependent Oligonucleotides Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global RNase H-dependent Oligonucleotides Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global RNase H-dependent Oligonucleotides Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Fomivirsen Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Fomivirsen Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Fomivirsen Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Inotersen Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Inotersen Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Inotersen Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Mipomersen Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Mipomersen Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Mipomersen Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Steric-Blocker Oligonucleotides Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Steric-Blocker Oligonucleotides Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Steric-Blocker Oligonucleotides Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Eteplirsen Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Eteplirsen Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Eteplirsen Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Golodirsen Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Golodirsen Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Golodirsen Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Nusinersen Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Nusinersen Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Nusinersen Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Aptamers Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Aptamers Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Aptamers Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global DNA Aptamers Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global DNA Aptamers Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global DNA Aptamers Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global RNA Aptamers Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global RNA Aptamers Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global RNA Aptamers Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global miRNA Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global miRNA Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global miRNA Therapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global mRNA Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global mRNA Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global mRNA Therapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global piRNA Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global piRNA Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global piRNA Therapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global siRNA Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global siRNA Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global siRNA Therapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Givosiran Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Givosiran Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Givosiran Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Patisiran Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Patisiran Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Patisiran Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Small Nucleic Acid Therapies Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 59. Global Oral Route Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Oral Route Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Oral Route Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Parenteral Route Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Parenteral Route Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Parenteral Route Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Small Nucleic Acid Therapies Market Size, by Delivery Mechanism, 2017-2032 (USD Million)
TABLE 75. Global GalNAc Conjugation Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global GalNAc Conjugation Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global GalNAc Conjugation Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Lipid Nanoparticles (LNPs) Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Lipid Nanoparticles (LNPs) Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Lipid Nanoparticles (LNPs) Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Polymer-Based Carriers Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Polymer-Based Carriers Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Polymer-Based Carriers Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global Viral Vectors Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Global Viral Vectors Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. Global Viral Vectors Market Size, by Country, 2017-2032 (USD Million)
TABLE 87. Global Small Nucleic Acid Therapies Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 88. Global Cardiovascular Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Global Cardiovascular Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. Global Cardiovascular Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 91. Global Genetic Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Global Genetic Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. Global Genetic Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 94. Global Duchenne Muscular Dystrophy (DMD) Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Global Duchenne Muscular Dystrophy (DMD) Market Size, by Group, 2017-2032 (USD Million)
TABLE 96. Global Duchenne Muscular Dystrophy (DMD) Market Size, by Country, 2017-2032 (USD Million)
TABLE 97. Global Spinal Muscular Atrophy (SMA) Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Global Spinal Muscular Atrophy (SMA) Market Size, by Group, 2017-2032 (USD Million)
TABLE 99. Global Spinal Muscular Atrophy (SMA) Market Size, by Country, 2017-2032 (USD Million)
TABLE 100. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 102. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 103. Global Bacterial Infections Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Global Bacterial Infections Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. Global Bacterial Infections Market Size, by Country, 2017-2032 (USD Million)
TABLE 106. Global Viral Infections Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Global Viral Infections Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. Global Viral Infections Market Size, by Country, 2017-2032 (USD Million)
TABLE 109. Global Inflammatory & Autoimmune Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 110. Global Inflammatory & Autoimmune Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. Global Inflammatory & Autoimmune Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 112. Global Psoriasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 113. Global Psoriasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 114. Global Psoriasis Market Size, by Country, 2017-2032 (USD Million)
TABLE 115. Global Rheumatoid arthritis Market Size, by Region, 2017-2032 (USD Million)
TABLE 116. Global Rheumatoid arthritis Market Size, by Group, 2017-2032 (USD Million)
TABLE 117. Global Rheumatoid arthritis Market Size, by Country, 2017-2032 (USD Million)
TABLE 118. Global Neurological Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 119. Global Neurological Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 120. Global Neurological Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 121. Global Alzheimer Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 122. Global Alzheimer Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 123. Global Alzheimer Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 124. Global Parkinson Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 125. Global Parkinson Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 126. Global Parkinson Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 127. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 128. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 129. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 130. Global Glioblastoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 131. Global Glioblastoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 132. Global Glioblastoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 133. Global Hepatocellular Carcinoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 134. Global Hepatocellular Carcinoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 135. Global Hepatocellular Carcinoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 136. Global Ophthalmic Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 137. Global Ophthalmic Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 138. Global Ophthalmic Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 139. Global Small Nucleic Acid Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 140. Global Academic & Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 141. Global Academic & Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 142. Global Academic & Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 143. Global Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
TABLE 144. Global Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
TABLE 145. Global Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
TABLE 146. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 147. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 148. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 149. Global Pharmaceutical & Biotechnology Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 150. Global Pharmaceutical & Biotechnology Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 151. Global Pharmaceutical & Biotechnology Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 152. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 153. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 154. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 155. Global Small Nucleic Acid Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 156. Asia-Pacific Small Nucleic Acid Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 157. Asia-Pacific Small Nucleic Acid Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 158. Asia-Pacific Small Nucleic Acid Therapies Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 159. Asia-Pacific Small Nucleic Acid Therapies Market Size, by RNase H-dependent Oligonucleotides, 2017-2032 (USD Million)
TABLE 160. Asia-Pacific Small Nucleic Acid Therapies Market Size, by Steric-Blocker Oligonucleotides, 2017-2032 (USD Million)
TABLE 161. Asia-Pacific Small Nucleic Acid Therapies Market Size, by Aptamers, 2017-2032 (USD Million)
TABLE 162. Asia-Pacific Small Nucleic Acid Therapies Market Size, by siRNA Therapeutics, 2017-2032 (USD Million)
TABLE 163. Asia-Pacific Small Nucleic Acid Therapies Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 164. Asia-Pacific Small Nucleic Acid Therapies Market Size, by Parenteral Route, 2017-2032 (USD Million)
TABLE 165. Asia-Pacific Small Nucleic Acid Therapies Market Size, by Delivery Mechanism, 2017-2032 (USD Million)
TABLE 166. Asia-Pacific Small Nucleic Acid Therapies Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 167. Asia-Pacific Small Nucleic Acid Therapies Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 168. Asia-Pacific Small Nucleic Acid Therapies Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 169. Asia-Pacific Small Nucleic Acid Therapies Market Size, by Inflammatory & Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 170. Asia-Pacific Small Nucleic Acid Therapies Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 171. Asia-Pacific Small Nucleic Acid Therapies Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 172. Asia-Pacific Small Nucleic Acid Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 173. North America Small Nucleic Acid Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 174. North America Small Nucleic Acid Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 175. North America Small Nucleic Acid Therapies Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 176. North America Small Nucleic Acid Therapies Market Size, by RNase H-dependent Oligonucleotides, 2017-2032 (USD Million)
TABLE 177. North America Small Nucleic Acid Therapies Market Size, by Steric-Blocker Oligonucleotides, 2017-2032 (USD Million)
TABLE 178. North America Small Nucleic Acid Therapies Market Size, by Aptamers, 2017-2032 (USD Million)
TABLE 179. North America Small Nucleic Acid Therapies Market Size, by siRNA Therapeutics, 2017-2032 (USD Million)
TABLE 180. North America Small Nucleic Acid Therapies Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 181. North America Small Nucleic Acid Therapies Market Size, by Parenteral Route, 2017-2032 (USD Million)
TABLE 182. North America Small Nucleic Acid Therapies Market Size, by Delivery Mechanism, 2017-2032 (USD Million)
TABLE 183. North America Small Nucleic Acid Therapies Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 184. North America Small Nucleic Acid Therapies Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 185. North America Small Nucleic Acid Therapies Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 186. North America Small Nucleic Acid Therapies Market Size, by Inflammatory & Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 187. North America Small Nucleic Acid Therapies Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 188. North America Small Nucleic Acid Therapies Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 189. North America Small Nucleic Acid Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 190. Latin America Small Nucleic Acid Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 191. Latin America Small Nucleic Acid Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 192. Latin America Small Nucleic Acid Therapies Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 193. Latin America Small Nucleic Acid Therapies Market Size, by RNase H-dependent Oligonucleotides, 2017-2032 (USD Million)
TABLE 194. Latin America Small Nucleic Acid Therapies Market Size, by Steric-Blocker Oligonucleotides, 2017-2032 (USD Million)
TABLE 195. Latin America Small Nucleic Acid Therapies Market Size, by Aptamers, 2017-2032 (USD Million)
TABLE 196. Latin America Small Nucleic Acid Therapies Market Size, by siRNA Therapeutics, 2017-2032 (USD Million)
TABLE 197. Latin America Small Nucleic Acid Therapies Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 198. Latin America Small Nucleic Acid Therapies Market Size, by Parenteral Route, 2017-2032 (USD Million)
TABLE 199. Latin America Small Nucleic Acid Therapies Market Size, by Delivery Mechanism, 2017-2032 (USD Million)
TABLE 200. Latin America Small Nucleic Acid Therapies Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 201. Latin America Small Nucleic Acid Therapies Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 202. Latin America Small Nucleic Acid Therapies Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 203. Latin America Small Nucleic Acid Therapies Market Size, by Inflammatory & Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 204. Latin America Small Nucleic Acid Therapies Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 205. Latin America Small Nucleic Acid Therapies Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 206. Latin America Small Nucleic Acid Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 207. Europe Small Nucleic Acid Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 208. Europe Small Nucleic Acid Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 209. Europe Small Nucleic Acid Therapies Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 210. Europe Small Nucleic Acid Therapies Market Size, by RNase H-dependent Oligonucleotides, 2017-2032 (USD Million)
TABLE 211. Europe Small Nucleic Acid Therapies Market Size, by Steric-Blocker Oligonucleotides, 2017-2032 (USD Million)
TABLE 212. Europe Small Nucleic Acid Therapies Market Size, by Aptamers, 2017-2032 (USD Million)
TABLE 213. Europe Small Nucleic Acid Therapies Market Size, by siRNA Therapeutics, 2017-2032 (USD Million)
TABLE 214. Europe Small Nucleic Acid Therapies Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 215. Europe Small Nucleic Acid Therapies Market Size, by Parenteral Route, 2017-2032 (USD Million)
TABLE 216. Europe Small Nucleic Acid Therapies Market Size, by Delivery Mechanism, 2017-2032 (USD Million)
TABLE 217. Europe Small Nucleic Acid Therapies Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 218. Europe Small Nucleic Acid Therapies Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 219. Europe Small Nucleic Acid Therapies Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 220. Europe Small Nucleic Acid Therapies Market Size, by Inflammatory & Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 221. Europe Small Nucleic Acid Therapies Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 222. Europe Small Nucleic Acid Therapies Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 223. Europe Small Nucleic Acid Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 224. Middle East Small Nucleic Acid Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 225. Middle East Small Nucleic Acid Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 226. Middle East Small Nucleic Acid Therapies Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 227. Middle East Small Nucleic Acid Therapies Market Size, by RNase H-dependent Oligonucleotides, 2017-2032 (USD Million)
TABLE 228. Middle East Small Nucleic Acid Therapies Market Size, by Steric-Blocker Oligonucleotides, 2017-2032 (USD Million)
TABLE 229. Middle East Small Nucleic Acid Therapies Market Size, by Aptamers, 2017-2032 (USD Million)
TABLE 230. Middle East Small Nucleic Acid Therapies Market Size, by siRNA Therapeutics, 2017-2032 (USD Million)
TABLE 231. Middle East Small Nucleic Acid Therapies Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 232. Middle East Small Nucleic Acid Therapies Market Size, by Parenteral Route, 2017-2032 (USD Million)
TABLE 233. Middle East Small Nucleic Acid Therapies Market Size, by Delivery Mechanism, 2017-2032 (USD Million)
TABLE 234. Middle East Small Nucleic Acid Therapies Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 235. Middle East Small Nucleic Acid Therapies Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 236. Middle East Small Nucleic Acid Therapies Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 237. Middle East Small Nucleic Acid Therapies Market Size, by Inflammatory & Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 238. Middle East Small Nucleic Acid Therapies Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 239. Middle East Small Nucleic Acid Therapies Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 240. Middle East Small Nucleic Acid Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 241. Africa Small Nucleic Acid Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 242. Africa Small Nucleic Acid Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 243. Africa Small Nucleic Acid Therapies Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 244. Africa Small Nucleic Acid Therapies Market Size, by RNase H-dependent Oligonucleotides, 2017-2032 (USD Million)
TABLE 245. Africa Small Nucleic Acid Therapies Market Size, by Steric-Blocker Oligonucleotides, 2017-2032 (USD Million)
TABLE 246. Africa Small Nucleic Acid Therapies Market Size, by Aptamers, 2017-2032 (USD Million)
TABLE 247. Africa Small Nucleic Acid Therapies Market Size, by siRNA Therapeutics, 2017-2032 (USD Million)
TABLE 248. Africa Small Nucleic Acid Therapies Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 249. Africa Small Nucleic Acid Therapies Market Size, by Parenteral Route, 2017-2032 (USD Million)
TABLE 250. Africa Small Nucleic Acid Therapies Market Size, by Delivery Mechanism, 2017-2032 (USD Million)
TABLE 251. Africa Small Nucleic Acid Therapies Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 252. Africa Small Nucleic Acid Therapies Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 253. Africa Small Nucleic Acid Therapies Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 254. Africa Small Nucleic Acid Therapies Market Size, by Inflammatory & Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 255. Africa Small Nucleic Acid Therapies Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 256. Africa Small Nucleic Acid Therapies Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 257. Africa Small Nucleic Acid Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 258. Global Small Nucleic Acid Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 259. ASEAN Small Nucleic Acid Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 260. ASEAN Small Nucleic Acid Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 261. ASEAN Small Nucleic Acid Therapies Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 262. ASEAN Small Nucleic Acid Therapies Market Size, by RNase H-dependent Oligonucleotides, 2017-2032 (USD Million)
TABLE 263. ASEAN Small Nucleic Acid Therapies Market Size, by Steric-Blocker Oligonucleotides, 2017-2032 (USD Million)
TABLE 264. ASEAN Small Nucleic Acid Therapies Market Size, by Aptamers, 2017-2032 (USD Million)
TABLE 265. ASEAN Small Nucleic Acid Therapies Market Size, by siRNA Therapeutics, 2017-2032 (USD Million)
TABLE 266. ASEAN Small Nucleic Acid Therapies Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 267. ASEAN Small Nucleic Acid Therapies Market Size, by Parenteral Route, 2017-2032 (USD Million)
TABLE 268. ASEAN Small Nucleic Acid Therapies Market Size, by Delivery Mechanism, 2017-2032 (USD Million)
TABLE 269. ASEAN Small Nucleic Acid Therapies Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 270. ASEAN Small Nucleic Acid Therapies Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 271. ASEAN Small Nucleic Acid Therapies Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 272. ASEAN Small Nucleic Acid Therapies Market Size, by Inflammatory & Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 273. ASEAN Small Nucleic Acid Therapies Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 274. ASEAN Small Nucleic Acid Therapies Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 275. ASEAN Small Nucleic Acid Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 276. GCC Small Nucleic Acid Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 277. GCC Small Nucleic Acid Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 278. GCC Small Nucleic Acid Therapies Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 279. GCC Small Nucleic Acid Therapies Market Size, by RNase H-dependent Oligonucleotides, 2017-2032 (USD Million)
TABLE 280. GCC Small Nucleic Acid Therapies Market Size, by Steric-Blocker Oligonucleotides, 2017-2032 (USD Million)
TABLE 281. GCC Small Nucleic Acid Therapies Market Size, by Aptamers, 2017-2032 (USD Million)
TABLE 282. GCC Small Nucleic Acid Therapies Market Size, by siRNA Therapeutics, 2017-2032 (USD Million)
TABLE 283. GCC Small Nucleic Acid Therapies Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 284. GCC Small Nucleic Acid Therapies Market Size, by Parenteral Route, 2017-2032 (USD Million)
TABLE 285. GCC Small Nucleic Acid Therapies Market Size, by Delivery Mechanism, 2017-2032 (USD Million)
TABLE 286. GCC Small Nucleic Acid Therapies Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 287. GCC Small Nucleic Acid Therapies Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 288. GCC Small Nucleic Acid Therapies Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 289. GCC Small Nucleic Acid Therapies Market Size, by Inflammatory & Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 290. GCC Small Nucleic Acid Therapies Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 291. GCC Small Nucleic Acid Therapies Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 292. GCC Small Nucleic Acid Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 293. European Union Small Nucleic Acid Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 294. European Union Small Nucleic Acid Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 295. European Union Small Nucleic Acid Therapies Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 296. European Union Small Nucleic Acid Therapies Market Size, by RNase H-dependent Oligonucleotides, 2017-2032 (USD Million)
TABLE 297. European Union Small Nucleic Acid Therapies Market Size, by Steric-Blocker Oligonucleotides, 2017-2032 (USD Million)
TABLE 298. European Union Small Nucleic Acid Therapies Market Size, by Aptamers, 2017-2032 (USD Million)
TABLE 299. European Union Small Nucleic Acid Therapies Market Size, by siRNA Therapeutics, 2017-2032 (USD Million)
TABLE 300. European Union Small Nucleic Acid Therapies Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 301. European Union Small Nucleic Acid Therapies Market Size, by Parenteral Route, 2017-2032 (USD Million)
TABLE 302. European Union Small Nucleic Acid Therapies Market Size, by Delivery Mechanism, 2017-2032 (USD Million)
TABLE 303. European Union Small Nucleic Acid Therapies Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 304. European Union Small Nucleic Acid Therapies Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 305. European Union Small Nucleic Acid Therapies Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 306. European Union Small Nucleic Acid Therapies Market Size, by Inflammatory & Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 307. European Union Small Nucleic Acid Therapies Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 308. European Union Small Nucleic Acid Therapies Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 309. European Union Small Nucleic Acid Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 310. BRICS Small Nucleic Acid Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 311. BRICS Small Nucleic Acid Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 312. BRICS Small Nucleic Acid Therapies Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 313. BRICS Small Nucleic Acid Therapies Market Size, by RNase H-dependent Oligonucleotides, 2017-2032 (USD Million)
TABLE 314. BRICS Small Nucleic Acid Therapies Market Size, by Steric-Blocker Oligonucleotides, 2017-2032 (USD Million)
TABLE 315. BRICS Small Nucleic Acid Therapies Market Size, by Aptamers, 2017-2032 (USD Million)
TABLE 316. BRICS Small Nucleic Acid Therapies Market Size, by siRNA Therapeutics, 2017-2032 (USD Million)
TABLE 317. BRICS Small Nucleic Acid Therapies Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 318. BRICS Small Nucleic Acid Therapies Market Size, by Parenteral Route, 2017-2032 (USD Million)
TABLE 319. BRICS Small Nucleic Acid Therapies Market Size, by Delivery Mechanism, 2017-2032 (USD Million)
TABLE 320. BRICS Small Nucleic Acid Therapies Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 321. BRICS Small Nucleic Acid Therapies Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 322. BRICS Small Nucleic Acid Therapies Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 323. BRICS Small Nucleic Acid Therapies Market Size, by Inflammatory & Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 324. BRICS Small Nucleic Acid Therapies Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 325. BRICS Small Nucleic Acid Therapies Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 326. BRICS Small Nucleic Acid Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 327. G7 Small Nucleic Acid Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 328. G7 Small Nucleic Acid Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 329. G7 Small Nucleic Acid Therapies Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 330. G7 Small Nucleic Acid Therapies Market Size, by RNase H-dependent Oligonucleotides, 2017-2032 (USD Million)
TABLE 331. G7 Small Nucleic Acid Therapies Market Size, by Steric-Blocker Oligonucleotides, 2017-2032 (USD Million)
TABLE 332. G7 Small Nucleic Acid Therapies Market Size, by Aptamers, 2017-2032 (USD Million)
TABLE 333. G7 Small Nucleic Acid Therapies Market Si

Companies Mentioned

  • ADARx Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Avidity Biosciences
  • BioNTech SE
  • bluebird bio, Inc.
  • Comanche Biopharma Corp.
  • Creyon Bio, Inc.
  • Eleven Therapeutics
  • Ferring B.V.
  • GenScript Biotech Corporation
  • Ionis Pharmaceuticals, Inc.
  • Moderna, Inc.
  • Nogra Pharma Limited
  • Novartis AG
  • Novo Nordisk A/S
  • OliX Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Ractigen Therapeutics
  • Regulus Therapeutics Inc.
  • SANOFI WINTHROP INDUSTRIE
  • Sarepta Therapeutics, Inc.
  • Silence Therapeutics
  • Sirnaomics Ltd.
  • Stoke Therapeutics, Inc.
  • Switch Therapeutics
  • Tevard Biosciences
  • Wave Life Sciences Ltd.

Related Topics

Related Reports

Nucleic Acid Labeling Market - Global Forecast 2026-2032 - Product Image

Nucleic Acid Labeling Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
Fully Automated Nucleic Acid Purification System Market - Global Forecast 2026-2032 - Product Image

Fully Automated Nucleic Acid Purification System Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Nucleic Acid Labeling - Global Strategic Business Report - Product Image

Nucleic Acid Labeling - Global Strategic Business Report

  • Report
  • 114 Pages
  • Global
From
Nucleic Acid Isolation and Purification Market Size, Share, Trends and Forecast by Product, Type, Method, End User, and Region, 2026-2034 - Product Image

Nucleic Acid Isolation and Purification Market Size, Share, Trends and Forecast by Product, Type, Method, End User, and Region, 2026-2034

  • Report
  • 149 Pages
  • Global
From
Nucleic Acid Isolation and Purification - Global Strategic Business Report - Product Image

Nucleic Acid Isolation and Purification - Global Strategic Business Report

  • Report
  • 161 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.